Phase 1 Colorectal cancer trials recruiting now

All Colorectal cancer trials, every phase

Other phases for Colorectal cancer

Phase 1 Colorectal cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
  NCT04689347 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
  NCT06298916 · Phase: Phase 1, Phase 2 · Ages: 15 Years and older · Sex: All (male and female) · 10 locations
• A Clinical Study of Arfolitixorin in Patients With mCRC
  NCT06922383 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  NCT06428409 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
  NCT06839105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
  NCT07079631 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
  NCT06043466 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
  NCT07186842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
  NCT07543744 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
  NCT07337525 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A First-In-Human Trial of pTTL in Advanced Colorectal Cancer
  NCT05908643 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
  NCT06783569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
  NCT07629960 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
  NCT05746897 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
  NCT06412198 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
  NCT07458347 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
  NCT07544589 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
  NCT07578571 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
  NCT07317505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
  NCT06270706 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors
  NCT06374173 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
  NCT07636785 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
  NCT06789172 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
  NCT07545122 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
  NCT06508307 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
  NCT06403735 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
  NCT06307925 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
  NCT05394714 · Phase: Phase 1 · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
  NCT06380816 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
  NCT06959615 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 64 locations
• A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
  NCT07283367 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer
  NCT07349043 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
  NCT06244771 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
  NCT05865002 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
  NCT04929223 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 84 locations
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
  NCT07217171 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
  NCT07244705 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP1002 in Adults for Treatment of Solid Tumors
  NCT05719558 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
  NCT07488676 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
  NCT05379595 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
  NCT05262491 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
  NCT06500052 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
  NCT04895709 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 94 locations
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
  NCT06764771 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
  NCT06730750 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
  NCT03526835 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
  NCT05759728 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of DEG6498 in Participants With Solid Tumors
  NCT07244835 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of DM002 in Patients With Advanced Solid Tumors
  NCT06751329 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
  NCT06983743 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 24 locations
• A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
  NCT07259590 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
  NCT07277270 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
  NCT05669430 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
  NCT05740956 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
  NCT07503808 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• A Study of JMT203 in Patients With Cancer Cachexia
  NCT06868849 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
  NCT06663319 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
  NCT07107230 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
  NCT07229313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Study of LY4257496 in Participants With Cancer (OMNIRAY)
  NCT07114601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
  NCT07213791 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MGC028 in Participants With Advanced Solid Tumors
  NCT06723236 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
  NCT07066657 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer
  NCT06663839 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
  NCT05877599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of PHN-012 in Patients With Advanced Solid Tumors
  NCT07127874 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 78 locations
• A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
  NCT07300150 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
  NCT03093116 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 165 locations
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
  NCT06385925 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 57 locations
• A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
  NCT07661641 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
  NCT07020117 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
  NCT05592626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 19 locations
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
  NCT05706129 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 40 locations
• A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
  NCT06598007 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
  NCT07749586 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
  NCT06179160 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
  NCT05093907 · Phase: Phase 1, Phase 2 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 120 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
  NCT06004245 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 43 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
  NCT07094204 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 20 locations
• A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
  NCT07169734 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
  NCT07416552 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
  NCT06720987 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations

Showing 100 of 279 recruiting trials.

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.